Evolus Inc. (EOLS)
NASDAQ: EOLS
· Real-Time Price · USD
10.00
0.81 (8.81%)
At close: Jun 02, 2025, 2:16 PM
8.81% (1D)
| Bid | 9.99 |
| Market Cap | 644.76M |
| Revenue (ttm) | 275.01M |
| Net Income (ttm) | -56.2M |
| EPS (ttm) | -0.89 |
| PE Ratio (ttm) | -11.24 |
| Forward PE | 16.39 |
| Analyst | Buy |
| Ask | 10.01 |
| Volume | 1,152,828 |
| Avg. Volume (20D) | 983,814 |
| Open | 9.28 |
| Previous Close | 9.19 |
| Day's Range | 9.17 - 10.04 |
| 52-Week Range | 8.67 - 17.82 |
| Beta | 1.12 |
About EOLS
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol EOLS
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for EOLS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 weeks ago
+1.29%
Evolus Shares Are Trading Lower After The Company ...
Unlock content with
Pro Subscription
3 months ago
+5.47%
Evolus shares are trading higher after the company announced FDA approval of Evolysse Form and Evolysse Smooth injectable hyaluronic acid gels.
2 weeks ago · businesswire.com
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in May of...
